Hunan Er-Kang Pharmaceutical Balance Sheet Health
Financial Health criteria checks 4/6
Hunan Er-Kang Pharmaceutical has a total shareholder equity of CN¥4.7B and total debt of CN¥399.4M, which brings its debt-to-equity ratio to 8.5%. Its total assets and total liabilities are CN¥5.4B and CN¥695.7M respectively.
Key information
8.5%
Debt to equity ratio
CN¥399.39m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥768.37m |
| Equity | CN¥4.70b |
| Total liabilities | CN¥695.74m |
| Total assets | CN¥5.39b |
Recent financial health updates
Hunan Er-Kang Pharmaceutical (SZSE:300267) Has Debt But No Earnings; Should You Worry?
Sep 26
Health Check: How Prudently Does Hunan Er-Kang Pharmaceutical (SZSE:300267) Use Debt?
Jun 03Recent updates
Subdued Growth No Barrier To Hunan Er-Kang Pharmaceutical Co., Ltd (SZSE:300267) With Shares Advancing 27%
Sep 30Hunan Er-Kang Pharmaceutical (SZSE:300267) Has Debt But No Earnings; Should You Worry?
Sep 26What Hunan Er-Kang Pharmaceutical Co., Ltd's (SZSE:300267) 28% Share Price Gain Is Not Telling You
Aug 08Health Check: How Prudently Does Hunan Er-Kang Pharmaceutical (SZSE:300267) Use Debt?
Jun 03Pinning Down Hunan Er-Kang Pharmaceutical Co., Ltd's (SZSE:300267) P/S Is Difficult Right Now
Mar 27Financial Position Analysis
Short Term Liabilities: 300267's short term assets (CN¥1.7B) exceed its short term liabilities (CN¥626.9M).
Long Term Liabilities: 300267's short term assets (CN¥1.7B) exceed its long term liabilities (CN¥68.8M).
Debt to Equity History and Analysis
Debt Level: 300267 has more cash than its total debt.
Reducing Debt: 300267's debt to equity ratio has increased from 0% to 8.5% over the past 5 years.
Debt Coverage: 300267's debt is well covered by operating cash flow (61.8%).
Interest Coverage: Insufficient data to determine if 300267's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 06:57 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hunan Er-Kang Pharmaceutical Co., Ltd is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yalei Yan | Bohai Securities Co., Ltd. |
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Jing Qiang | China International Capital Corporation Limited |